What is Glenmark Pharmaceuticals Ltd's PE ratio?

Glenmark Pharmaceuticals Ltd trades at a P/E ratio of 21.00.

What is Glenmark Pharmaceuticals Ltd's market cap?

Glenmark Pharmaceuticals Ltd's market capitalisation is ₹61,858 Cr.

When are Glenmark Pharmaceuticals Ltd's next results?

Glenmark Pharmaceuticals Ltd's next earnings date is 31 Jul '26.

What is Glenmark Pharmaceuticals Ltd's ROE?

Glenmark Pharmaceuticals Ltd's return on equity (ROE) is 30.5%.

What sector is Glenmark Pharmaceuticals Ltd in?

Glenmark Pharmaceuticals Ltd (GLENMARK) is classified in the Healthcare sector (Pharmaceuticals).

Healthcare · Pharmaceuticals

Glenmark Pharmaceuticals Ltd (GLENMARK)

₹2,192.00

Mkt cap

₹61,858 Cr

P/E ratio

21.00

P/B

5.89

Div yield

0.11%

ROE

30.50%

ROCE

39.80%

EPS (TTM)

₹104.38

Book value

₹372

52W range

1,810–2,418

Sector

Healthcare

Glenmark Pharmaceuticals Ltd is a global research-led pharmaceutical company with presence across generics, Specialty and OTC business with operations in over 80 countries. [1]

NSE GLENMARKBSE 532296www.glenmarkpharma.com

Health check

Constructive

ValuationCheap

ProfitabilityStrong

GrowthModerate

TechnicalsNeutral

52-week range

−9.34% from high

₹2,192

₹1,810+21.08% from low₹2,418

Current

₹2,192.00

Prev close

₹2,214.50

Day

−1.02%

Price performance

−1.02%

−2.12%

+1.75%

−4.67%

+13.28%

−1.56%

YTD

+6.18%

Financials

F

Revenue, profit & margin

P/E ratio

21.0×

GLENMARK is 38% below the sector median of 34.0×

GLENMARK21.0×

Sector median34.0×

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Sales	3,001	3,036	3,207	2,507	3,063	3,244	3,434	3,388	3,256	3,264	6,047	3,901	3,771
Expenses	2,603	2,599	2,745	2,715	2,559	2,656	2,832	2,787	2,695	2,684	3,687	3,031	3,008
Operating Profit	398	437	462	-209	504	588	602	600	561	581	2,360	870	763
OPM %	13%	14%	14%	-8%	16%	18%	18%	18%	17%	18%	39%	22%	20%
Other Income	-696	-32	-205	87	351	31	39	31	-361	-297	-1,184	-140	-184
Interest	109	112	121	134	149	40	48	52	67	58	66	41	43
Depreciation	135	142	141	147	151	118	120	123	125	130	141	154	148
Profit before tax	-542	151	-6	-403	555	462	473	456	8	96	967	534	388
Tax %	-26%	-14%	997%	-18%	319%	26%	25%	24%	45%	51%	37%	24%	22%
Net Profit	-403	173	-62	-331	-1,214	340	354	348	4	47	610	403	301
EPS in Rs	-15.18	5.31	-2.90	-12.45	-43.17	12.06	12.55	12.33	0.16	1.66	21.63	14.29	10.68
Raw PDF

Earnings

EResults dates & reactions

Next results

31 Jul '26scheduled

Fresh quarters land in the Financials table above, tagged NSE until screener catches up.

Avg earnings-day move +0.03% · closed higher next day 21 of last 61

	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25	Q4FY25	Q1FY26	Q2FY26	Q3FY26	Q4FY26
Broadcast	11 Aug '23◦	10 Nov '23◦	14 Feb '24◦	24 May '24◦	14 Aug '24◦	15 Nov '24◦	14 Feb '25◦	23 May '25◦	14 Aug '25◦	14 Nov '25◦	30 Jan '26◦	29 May '26◦
Earnings day	−0.46%	−6.87%	+1.64%	+8.06%	+5.00%	−3.13%	+3.84%	−2.12%	−3.46%	−1.41%	−4.74%	−3.24%
+1 day	−0.49%	−3.45%	+9.41%	+11.99%	+9.41%	−2.68%	+4.25%	−2.48%	−4.83%	−2.79%	−3.06%	−3.97%
+5 days	−5.28%	−0.03%	+14.46%	+13.53%	+13.11%	−0.80%	+0.16%	+5.44%	−4.33%	−2.81%	−2.06%	−4.33%
+15 days	−1.20%	+3.68%	+19.83%	+19.97%	+14.18%	+0.58%	+5.83%	+18.53%	+3.51%	+1.39%	+1.16%	−3.65%
+30 days	−3.11%	+9.97%	+23.81%	+31.18%	+13.04%	+5.27%	+16.79%	+30.97%	−4.49%	+7.08%	+6.45%	+1.33%
Filing	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	XBRL	PDF	PDF	XBRL	XBRL	XBRL

Corporate actions

CLast 6 months

No recent corporate actions

Dividends, splits, and bonuses in the last six months show up here.

Shareholding

Sas of Jun 2026

46.65%Promoter

Promoters46.65%

FIIs20.89%0.54

DIIs18.60%0.68

Public13.81%0.11

Government0.04%

Ownership trend

Peers

P8 companies

Valuation vs quality

P/E × ROCE · bubble = market cap

Name	CMP	P/E	Mkt Cap	Div Yld	NP Qtr	Qtr Profit Var	Sales Qtr	Qtr Sales Var	ROCE
Sun Pharma.Inds.	₹1,941.10	37.48	4,65,735	0.82%	2,710	+13.58%	14,612	+12.76%	20.53%
Divi's Lab.	₹7,248.50	73.36	1,92,425	0.41%	751	+13.44%	2,831	+9.52%	21.97%
Torrent Pharma.	₹4,961.50	86.11	1,88,720	0.77%	364	−20.58%	4,197	+41.84%	15.19%
Cipla	₹1,410.60	31.84	1,13,955	0.92%	786	−39.19%	7,119	+2.33%	15.49%
Zydus Lifesci.	₹1,108.70	20.38	1,10,593	0.09%	1,341	+21.92%	7,587	+16.22%	21.14%
Lupin	₹2,370.50	19.06	1,08,387	0.76%	1,469	+101.49%	7,475	+31.89%	29.93%
Mankind Pharma	₹2,507.20	51.44	1,03,546	0.04%	559	+34.23%	3,443	+11.81%	13.53%
Glenmark Pharma.	₹2,192.00	20.96	61,858	0.11%	301	+51.88%	3,771	+15.80%	39.77%
Median: 157 Co.	₹432.05	34.03	1,978	0.10%	15	+28.10%	176	+17.66%	15.10%

Filings

D

Annual reports15

Financial Year 2025bse Financial Year 2024bse Financial Year 2023bse Financial Year 2022bse Financial Year 2021bse Financial Year 2020bse Financial Year 2019bse Financial Year 2018bse Financial Year 2017bse Financial Year 2016bse Financial Year 2015bse Financial Year 2014bse Financial Year 2013nse Financial Year 2013bse Financial Year 2012bse

Credit ratings6

Rating update 11 Febcrisil Rating update 18 Sep 2025crisil Rating update 23 Jul 2025fitch Rating update 18 Jun 2025crisil Rating update 25 Apr 2024fitch Rating update 25 Apr 2024fitch

Announcements5

Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Jul - Glenmark Pharmaceuticals schedules Q1 FY2027 earnings call on August 3, 2026, at 8:30 am IST.Announcement under Regulation 30 (LODR)-Press Release / Media Release 21 Jul - U.S. FDA approves RYALTRIS for children 6 to under 12, expanding Glenmark's U.S. respiratory portfolio.Board Meeting Intimation for Considering And Approving Unaudited Financial Results Of Glenmark Pharmaceuticals Limited For The Quarter Ended June 30, 2026 15 Jul - Board meets July 31, 2026 to approve Q1 FY27 unaudited standalone and consolidated results.Announcement under Regulation 30 (LODR)-Press Release / Media Release 6 Jul - Glenmark USA launched Olanzapine for Injection 10 mg/vial on July 6, 2026.Announcement under Regulation 30 (LODR)-Press Release / Media Release 2 Jul - Glenmark advances Phase 3 trastuzumab rezetecan trial for platinum-resistant ovarian cancer; India enrollment begins after DCGI approval.